Bleomycin A6

Glycopeptide AntibioticRx: PrescriptionCompound: Approved

Also known as: Bleomycin A6, Bleomycin A6 (Pinyangmycin), Bleomycin sulfate, BLM A6, BLM-A6, Boanmycin, Pingyangmycin

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Source Bleomycin A6 at Peptiology

Save 10% with code PEPTI-BOSSRABBIT-10

Shop Now & Save 10% →

Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.

Summary

Bleomycin A6 is a component of the bleomycin mixture used as an antineoplastic agent; it induces DNA cleavage leading to tumor cell death.

Mechanism of Action

Binds Fe2+ and DNA, generating free radicals that cause DNA strand breaks and inhibit replication

Routes of Administration

IntralesionalIntramuscularIntravenousSubcutaneous

Goals & Uses

  • Hodgkin lymphoma treatmentOncologyHigh
  • Lymphoma treatmentOncologyModerate
  • Testicular carcinoma treatmentOncologyModerate
  • Hemangioma treatmentDermatology/PediatricsLow
  • Squamous cell carcinoma treatmentOncologyModerate
  • Vascular malformation sclerotherapyInterventional RadiologyModerate
  • Testicular cancer adjuvant therapyOncologyHigh

Contraindications

  • Severely impaired renal functionRenalHigh
  • Hypersensitivity to bleomycin compoundsImmunologicHigh
  • Known hypersensitivity to bleomycinImmuneHigh
  • PregnancyPopulationHighPotential fetal risk or insufficient safety data
  • Pulmonary fibrosis or severe lung diseasePulmonaryHigh
  • Pulmonary fibrosisRespiratoryHigh

Adverse Effects

  • Oral mucositis / stomatitisMucosalUncommon
  • Fever and chillsConstitutionalCommon
  • Nausea and vomitingGastrointestinalUncommon
  • Anaphylactoid reactionImmunologicRare
  • MucositisGastrointestinal / MucosalUncommon
  • Skin hyperpigmentationDermatologicCommon
  • Pulmonary toxicity / pulmonary fibrosisPulmonaryUncommon
  • Pulmonary toxicityRespiratoryCommon
  • Mucocutaneous toxicity (skin thickening, hyperpigmentation, alopecia)DermatologicCommon

Drug Interactions

  • Supplemental oxygen (high FiO2)High
  • G-CSF / GM-CSFModerate
  • CisplatinHigh
  • Vinca alkaloids (vincristine, vinblastine)Low
  • High inspired oxygen concentrationsHigh
  • Other DNA‑damaging agents (e.g., cisplatin)Moderate

Population Constraints

  • Renal impairmentOrgan ImpairmentRelative
  • Pediatric patientsAgeRelative
  • Pregnant or breastfeeding womenReproductiveAbsolute
  • Patients with renal impairmentOrgan ImpairmentRelative
  • Elderly patientsAgeRelative
  • Elderly patients (≥65 years)Age RelatedRelative

Regulatory Status

  • European UnionApprovedApproved: Hodgkin lymphoma, Testicular cancerEMA approval with similar restrictions on pulmonary toxicity.
  • United StatesApprovedApproved: Hodgkin lymphoma, Testicular cancer, Squamous cell carcinoma of head and neckFDA‑approved as bleomycin sulfate for IV/IM administration.
  • United KingdomUnapprovedMHRA approvals cover bleomycin sulfate (A2/B2); Bleomycin A6 not separately licensed.

Approved for Hodgkin lymphoma, testicular cancer, squamous cell carcinoma of the head and neck; dosing limited by pulmonary toxicity risk.

Evidence & Sources

No sources recorded yet.

Frequently Asked Questions

What is Bleomycin A6?

Bleomycin A6 is a component of the bleomycin mixture used as an antineoplastic agent; it induces DNA cleavage leading to tumor cell death.

What is Bleomycin A6 used for?

Bleomycin A6 is educationally associated with: Hodgkin lymphoma treatment, Lymphoma treatment, Testicular carcinoma treatment, Hemangioma treatment, Squamous cell carcinoma treatment, Vascular malformation sclerotherapy, Testicular cancer adjuvant therapy. Educational only — not medical advice.

How is Bleomycin A6 administered?

Recorded routes of administration: Intralesional, Intramuscular, Intravenous, Subcutaneous.

What are the potential side effects of Bleomycin A6?

Reported adverse effects include: Oral mucositis / stomatitis, Fever and chills, Nausea and vomiting, Anaphylactoid reaction, Mucositis, Skin hyperpigmentation, Pulmonary toxicity / pulmonary fibrosis, Pulmonary toxicity, Mucocutaneous toxicity (skin thickening, hyperpigmentation, alopecia). This list is not exhaustive — consult a qualified clinician.

Who should avoid Bleomycin A6?

Recorded contraindications: Severely impaired renal function, Hypersensitivity to bleomycin compounds, Known hypersensitivity to bleomycin, Pregnancy, Pulmonary fibrosis or severe lung disease, Pulmonary fibrosis. Consult a qualified clinician before use.

More in this class